微生物来源苯乙酰谷氨酰胺与CKD患者全因死亡和心血管疾病相关
研究前瞻性随访488例CKD 1-5期患者,采用液相色谱-质谱法测定血清苯乙酰谷氨酰胺。血清苯乙酰谷氨酰胺水平与全因死亡(校正后每增加1个标准差HR 1.77,95%CI 1.22-2.57,P=0.003)和心血管疾病(HR 1.79,95%CI 1.32-2.41,P<0.001)独立相关。
要点
- 血清苯乙酰谷氨酰胺与24小时尿排泄量(rho=0.55,P<0.001)及肾脏清除率(rho=-0.76,P<0.001)相关。
- 校正年龄、性别、糖尿病、既往心血管疾病和eGFR后,苯乙酰谷氨酰胺仍与死亡和心血管疾病独立相关。
- 血清苯乙酰谷氨酰胺水平随CKD进展而升高,且不能完全由eGFR差异解释。
核心结论
- 高血清苯乙酰谷氨酰胺水平是全因死亡和心血管疾病的强独立危险因素,提示微生物代谢和/或小管功能障碍在CKD中的相关性,且不依赖于蛋白结合。
研究设计与样本
- 前瞻性随访488例CKD 1-5期患者,采用液相色谱-质谱法测定血清苯乙酰谷氨酰胺;在亚组中测定24小时尿排泄量和肾脏清除率。
主要发现
- 血清苯乙酰谷氨酰胺水平与24小时尿排泄量相关(rho=0.55;P<0.001),与苯乙酰谷氨酰胺清除率相关(rho=-0.76;P<0.001)。
- 苯乙酰谷氨酰胺清除率与eGFR相关(rho=0.84;P<0.001)。
- 校正年龄、性别、糖尿病、既往心血管疾病和eGFR后,血清苯乙酰谷氨酰胺水平与全因死亡相关(每增加1个标准差HR 1.77;95%CI 1.22-2.57;P=0.003),与心血管疾病相关(HR 1.79;95%CI 1.32-2.41;P<0.001)。
- 共观察到51例死亡事件和75例心血管疾病事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colonic microbial metabolism substantially contributes to uremic solute production. p-Cresyl sulfate and indoxyl sulfate are the main representatives of solutes of microbial origin and also, protein-bound solutes, exhibiting high protein-binding affinity and dependence on tubular secretion. Phenylacetylglutamine is another microbial metabolite with high dependence on tubular secretion but low protein-binding affinity. The relevance of such solutes is unknown. Therefore, we prospectively followed 488 patients with CKD stages 1-5 and a measurement of serum phenylacetylglutamine by liquid chromatography-mass spectrometry. In a subgroup, we determined 24-hour urinary excretion as a surrogate of intestinal uptake as well as renal clearance of phenylacetylglutamine. We performed outcome analysis for mortality (51 events) and cardiovascular disease (75 events). Serum phenylacetylglutamine level correlated with 24-hour urinary excretion (rho=0.55; P<0.001) and clearance of phenylacetylglutamine (rho=-0.76; P<0.001). Phenylacetylglutamine clearance also correlated with eGFR (rho=0.84; P<0.001). Furthermore, serum phenylacetylglutamine level associated with mortality (hazard ratio per 1-SD increase, 1.77; 95% confidence interval, 1.22 to 2.57; P=0.003) and cardiovascular disease (hazard ratio, 1.79; 95% confidence interval, 1.32 to 2.41; P<0.001) after adjustment for age, sex, presence of diabetes mellitus, prior cardiovascular disease, and eGFR. Thus, serum phenylacetylglutamine level is elevated in patients with more advanced CKD and determined by intestinal uptake and renal clearance, and it is not fully accounted for by differences in eGFR. High serum phenylacetylglutamine level is a strong and independent risk factor for mortality and cardiovascular disease, suggesting the relevance of microbial metabolism and/or tubular dysfunction in CKD, irrespective of protein binding.
引用
- Poesen R, Claes K, Evenepoel P, et al. Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. J Am Soc Nephrol. 2016. PMID: 27230658
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。